QR-Code

11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

Abstract Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiati...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Radek Lakomý, Martina Lojová, Lenka Souckova, Ludmila Hynkova, Katerina Polachova, Jiri Vasina, Regina Demlová, Alexandr Poprach, Jiri Sana, Tomas Prochazka, Martin Smrcka, Pavel Fadrus, Radim Jancalek, Iveta Selingerova, Renata Belanova, Pavel Slampa, Petr Pospisil, Tomas Kazda
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2024-06-01
Schriftenreihe:BMC Cancer
Schlagworte:
Glioblastoma
Rapid early progression
Radiopharmaceutical
11C-methionine
Clinical trial
Positron emission tomography
Online-Zugang:https://doi.org/10.1186/s12885-024-12469-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge